<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03143517</url>
  </required_header>
  <id_info>
    <org_study_id>CALFE Sample Collection C-001</org_study_id>
    <nct_id>NCT03143517</nct_id>
  </id_info>
  <brief_title>Fecal Calprotectin Collection Protocol</brief_title>
  <acronym>CALFE</acronym>
  <official_title>CALFE Stool Sample Collection Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DiaSorin Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DiaSorin Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to obtain stool samples from subjects diagnosed with , and
      displaying signs and/or symptoms of IBD and/or IBS will be evaluated in this study. Eligible
      subjects require a diagnostic colonoscopy with possible biopsy and clinical evaluation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stools will be collected and tested, at a later date, in a clinical performance study with an
      investigational Calprotectin assay. This study will be coordinated by the Sponsor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Calprotectin Stool Collection</measure>
    <time_frame>Through Study Completion, an average of 1 year</time_frame>
    <description>In vitro diagnostic (IVD) device performance</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Crohn Disease</condition>
  <condition>Indeterminate Colitis</condition>
  <condition>Chronic Diarrhea</condition>
  <condition>Celiac Disease</condition>
  <condition>Diverticulitis</condition>
  <condition>Abdominal Pain</condition>
  <condition>Distension</condition>
  <condition>Weight Loss</condition>
  <condition>Food Intolerance</condition>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>Inflammatory Bowel Disease (IBD)</arm_group_label>
    <description>A stool sample will be collected from adult subjects with Inflammatory Bowel Disease (IBD), confirmed by endoscopy and histologic examination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irritable Bowel Syndrome (IBS)</arm_group_label>
    <description>A stool sample will be collected from adult subjects with adult subjects with Irritable Bowel Syndrome meeting the Rome III criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other GastroIntestinal (GI) Disorders</arm_group_label>
    <description>A stool sample will be collected from adult subjects with adult subjects with gastrointestinal disorders other than IBD or IBS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Stool collection</intervention_name>
    <description>Stool sample collected by a subject who have been diagnosed with IBD, IBS or other GI disorder. The stool sample is tested in a laboratory where fecal calprotectin levels are quantified.</description>
    <arm_group_label>Inflammatory Bowel Disease (IBD)</arm_group_label>
    <arm_group_label>Irritable Bowel Syndrome (IBS)</arm_group_label>
    <arm_group_label>Other GastroIntestinal (GI) Disorders</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Human Stool
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult subjects and belonging to the target population, i.e. patients diagnosed with IBD,
        specifically CD, UC, or IC, patients diagnosed with IBS, and patients diagnosed with other
        gastrointestinal diseases, e.g. Celiac Disease, Diverticular Disease, Chronic Diarrhea and
        Recurrent Abdominal Pain (RAP).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is of either gender and â‰¥ 4 years of age.

          -  Subject is showing signs and symptoms of IBD and/or IBS.

          -  Diagnosis of IBD, IBS or other gastrointestinal disorder is performed by colonoscopy.

          -  Subject or authorized legal representative is willing and able to sign the IRB
             approved Informed Consent form or able to provide Informed Consent in accordance with
             21 CFR 50 CFR 50 Subpart B.

          -  Subject is able to understand and follow study sample collection procedure.

        Exclusion Criteria:

          -  Subject has undergone a surgical resection or diversion procedure.

          -  Subject is currently taking NSAIDS (non-steroidal anti-inflammatory drugs, i.e.
             ibuprofen, Advil, Motrin, Naproxen, Aleve including regular dose and low dose aspirin)
             within 7 days of colonoscopy and sample collection.

          -  Subject who has taken immunomodulators or biologic therapies within the previous 6
             months of colonoscopy and sample collection.

          -  Subject who is currently pregnant or lactating.

          -  Subject is unable or unwilling to follow informed consent.

          -  Inability or unwilling to perform required study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical DiaSorin</last_name>
    <phone>651-439-9710</phone>
    <email>Clinical@diasorin.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>One (1) Facility in Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>One (1) Location in California</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>One (1) Location in Colorado Springs, Colorado</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>One (1) Location in Miami, Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>One (1) Location in St. Augustine, FL</name>
      <address>
        <city>Saint Augustine</city>
        <state>Florida</state>
        <zip>32086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>One (1) Location in New York, New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>One (1) Location in North Carolina</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2017</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammatory Bowel Diseases</keyword>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>Crohn Disease</keyword>
  <keyword>Indeterminate Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Abdominal Pain</mesh_term>
    <mesh_term>Celiac Disease</mesh_term>
    <mesh_term>Diverticulitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

